Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lumos Pharma (LUMO)
NASDAQ:LUMO
Holding LUMO?
Track your performance easily
LUMO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.37 - $4.58
Previous Close$4.39
Volume56.22K
Average Volume (3M)97.29K
Market Cap
$35.87M
Enterprise Value$19.52M
Total Cash (Recent Filing)$16.80M
Total Debt (Recent Filing)$449.00K
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Nov 12, 2024EPS Estimate
-$0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.43
Shares Outstanding8,124,037
10 Day Avg. Volume99,732
30 Day Avg. Volume97,286
Standard Deviation0.31
R-Squared0.02
Alpha0.00832
Financial Highlights & Ratios
Price to Book (P/B)3.39
Price to Sales (P/S)24.00
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue16.44
Enterprise Value/Gross Profit9.52
Enterprise Value/Ebitda-0.54
Forecast
1Y Price Target
$8.17Price Target Upside89.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Lumos Pharma News
PremiumCompany Announcements
Lumos Pharma Faces Uncertainty as CVRs Risk Expiring Worthless Post-Merger
Bulls Say, Bears Say
Bulls Say
AcquisitionLumos' board unanimously determined that the acquisition by Double Point Ventures is in the best interests of all Lumos Pharma stockholders.
Clinical Trial SuccessThe company met all primary and secondary endpoints in its Phase 2 OraGrowtH210 and OraGrowtH212 studies of LUM-201 in PGHD.
Regulatory ApprovalLumos announced that the FDA is aligned with the company on the final Phase 3 trial design for LUM-201 in pediatric growth hormone deficiency patients.
Bears Say
Cash FlowLumos Pharma's cash runway is limited to the fourth quarter of 2024, restricting better alternatives for the company.
Financial GuidanceThe prior runway guidance has been withdrawn, and the company provided no updated guidance.
ValuationThe valuation of the merger with Double Point Ventures is considered disappointing, with a modest premium to the stock's recent price.
---
Ownership Overview
19.37% Insiders
3.99% Mutual Funds
1.14% Other Institutional Investors
72.53% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LUMO FAQ
What was Lumos Pharma’s price range in the past 12 months?
Lumos Pharma lowest stock price was $1.37 and its highest was $4.58 in the past 12 months.
What is Lumos Pharma’s market cap?
Currently, no data Available
When is Lumos Pharma’s upcoming earnings report date?
Lumos Pharma’s upcoming earnings report date is Nov 12, 2024 which is in 2 days.
How were Lumos Pharma’s earnings last quarter?
Lumos Pharma released its earnings results on Aug 01, 2024. The company reported -$0.93 earnings per share for the quarter, beating the consensus estimate of -$1.173 by $0.243.
Is Lumos Pharma overvalued?
According to Wall Street analysts Lumos Pharma’s price is currently Undervalued.
Does Lumos Pharma pay dividends?
Lumos Pharma does not currently pay dividends.
What is Lumos Pharma’s EPS estimate?
Lumos Pharma’s EPS estimate is -$0.74.
How many shares outstanding does Lumos Pharma have?
Lumos Pharma has 8,124,037 shares outstanding.
What happened to Lumos Pharma’s price movement after its last earnings report?
Lumos Pharma reported an EPS of -$0.93 in its last earnings report, beating expectations of -$1.173. Following the earnings report the stock price went up 4.469%.
Which hedge fund is a major shareholder of Lumos Pharma?
Among the largest hedge funds holding Lumos Pharma’s share is Blackstone Inc.. It holds Lumos Pharma’s shares valued at N/A.
---
Lumos Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.17 (89.56% Upside)
$8.17 (89.56% Upside)
Hedge Fund Trend
Decreased
By 78.6K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.78%
12-Months-Change
Fundamentals
Return on Equity
-132.56%
Trailing 12-Months
Asset Growth
-62.12%
Trailing 12-Months
Company Description
Lumos Pharma
NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.
---
LUMO Earnings Call
Q2 2024
0:00 / 0:00
---
LUMO Stock 12 Month Forecast
Average Price Target
$8.17
▲(89.56% Upside)
Technical Analysis
Best Analysts Covering LUMO
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
+9.09%
reiterated a buy rating 3 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +9.09% per trade.
---